BioNTech sues Moderna for patent infringement over COVID-19 shots

Core Viewpoint - BioNTech has initiated a lawsuit against Moderna in Delaware federal court, claiming that Moderna's COVID-19 vaccine, mNexspike, infringes on a patent related to BioNTech and Pfizer's vaccine, Comirnaty [1]. Company Summary - BioNTech is asserting its intellectual property rights in the biopharmaceutical sector by targeting Moderna for alleged patent infringement [1]. - Moderna's mNexspike vaccine is at the center of the legal dispute, indicating potential competitive tensions in the COVID-19 vaccine market [1]. Industry Context - The lawsuit highlights ongoing legal battles within the biopharmaceutical industry, particularly concerning vaccine patents and intellectual property rights amid the COVID-19 pandemic [1].